Drugs.com New Drug ApplicationsOriginal article
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-Positive NSCLC
NDA FilingNeladalkibPositive
AI Analysis
Summary
Nuvalent announced the submission of a New Drug Application to the FDA for neladalkib in TKI pre-treated advanced ALK-positive non-small cell lung cancer. This regulatory milestone represents a significant step toward potential commercialization of the candidate therapy.
Outcome Details
New Drug Application submitted to FDA
Importance:7/10
Sentiment:
0.60
NDA submissionFDA regulatoryoncologyNSCLCALK-positive
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on April 7, 2026 7:04 PM